Clinical Trial Detail

NCT ID NCT03621982
Title Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors ADC Therapeutics S.A.
Indications

ovarian cancer

Advanced Solid Tumor

head and neck cancer

transitional cell carcinoma

pancreatic cancer

esophageal cancer

renal cell carcinoma

triple-receptor negative breast cancer

lung non-small cell carcinoma

melanoma

stomach cancer

Therapies

Camidanlumab Tesirine

Age Groups: adult senior

No variant requirements are available.